A influência da lateralização cortical no controle motor seletivo do balanço do braço durante a caminhada independente após acidente vascular cerebral.
The upper limbs play an essential role for safe and efficient walking in healthy persons and persons post-stroke. Nevertheless, in current post-stroke gait rehabilitation (research) the upper limbs are barely targeted. To address this gap, my project aims to investigate the selective motor control of the upper limbs during walking and the contribution of the cortical activity to the arm swing in independent walkers after stroke.
To gain insight in the direct effects of stroke on the arm swing, the primary motor control of the arm swing will be evaluated by determining muscle synergies (i.e group of muscles working together as a task-specific functional unit). Additionally, the cortical activity (EEG-analysis) during walking of persons post-stroke will be compared to healthy controls and the relationship between stroke-induced changes in cortical activity and arm swing deviations will be assessed. Furthermore, I will evaluate whether improvements in cortical activity relate to improvements in primary motor control of the arm swing.
This innovative project will be the first to investigate the direct coupling between the cortex and the muscle synergies in persons post-stroke during independent walking to investigate the arm swing. These fundamental insights in the primary motor control of the arm swing and the contribution of the cortical activity will allow to develop targeted interventions aiming to improve arm swing and as such optimize post-stroke gait rehabilitation.
Research questions:
- How can muscle synergies explain arm swing alterations in independent walkers after stroke?
- How do stroke-induced changes in cortical activity relate to arm swing deviations in persons after stroke?
- Are changes in primary motor control of the upper limb during walking related to normalization of brain activity in independent walkers after stroke?
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Anke Van Bladel, PhD
- Número de telefone: 09 332 12 43
- E-mail: Anke.VanBladel@UGent.be
Estude backup de contato
- Nome: Arne Defour, Msc.
- Número de telefone: 09 332 12 43
- E-mail: Arne.Defour@UGent.be
Locais de estudo
-
-
-
Diepenbeek, Bélgica, 3590
- Recrutamento
- UHasselt - Faculteit Revalidatiewetenschappen
-
Contato:
- Arne Defour
- Número de telefone: 093321243
- E-mail: arne.defour@ugent.be
-
Contato:
- Sophie De Mits
- Número de telefone: 093321243
- E-mail: Sophie.DeMits@UGent.be
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Bélgica
- Recrutamento
- Ghent University Hospital
-
Investigador principal:
- Arne Defour, Msc.
-
Contato:
- Anke Van Bladel, PhD
- Número de telefone: 093321243
- E-mail: Sophie.DeMits@UGent.be
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Stroke
Inclusion Criteria:
- First-ever and cerebral stroke
- Able to walk at least 10 minutes (FAC ≥ 3)
- Presence of upper limb paresis (NIHSS item 5a/b > 0)
Exclusion Criteria:
- Other neurological disorders
Healthy controls
Inclusion criteria:
- Older than 18 years
- Able to walk at least 10 minutes
Exlusion criteria:
- Pregnancy
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Stroke
Persons with a unilateral first ever stroke |
Participants have to walk without holding handrails and without bodyweight support for at least 200 gait cycles. They are asked to walk at comfortable walking speed while watching forward to a screen without virtual reality projection. Arm should be next to the body to allow arm swing if possible. |
|
Comparador Ativo: Control
Age and gender matched healthy controls |
Participants have to walk without holding handrails and without bodyweight support for at least 200 gait cycles. They are asked to walk at comfortable walking speed while watching forward to a screen without virtual reality projection. Arm should be next to the body to allow arm swing if possible. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of muscle synergies
Prazo: Single point of assessment at inclusion
|
The number of muscle synergies needed to account for 90% variance in muscle activity measured by surface EMG during walking in stroke survivors compared to healthy controls. Following muscles will be examined:
|
Single point of assessment at inclusion
|
|
Number of muscle synergies
Prazo: Single point of assessment 3 months after inclusion (only for stroke survivors)
|
The number of muscle synergies needed to account for 90% variance in muscle activity measured by surface EMG during walking in stroke survivors after a follow-up period of three months. Following muscles will be examined:
|
Single point of assessment 3 months after inclusion (only for stroke survivors)
|
|
Weight of muscle synergies
Prazo: Single point of assessment at inclusion
|
The number or distribution of muscle weightings within a synergy during walking in stroke survivors compared to healthy controls. The distribution of muscle activation averages over one gait cycle measured by surface EMG of following muscles:
|
Single point of assessment at inclusion
|
|
Weight of muscle synergies
Prazo: Single point of assessment 3 months after inclusion (only for stroke survivors)
|
The number or distribution of muscle weightings within a synergy during walking in stroke survivors after a follow-up period of three months. The distribution of muscle activation averages over one gait cycle measured by surface EMG of following muscles:
|
Single point of assessment 3 months after inclusion (only for stroke survivors)
|
|
Brain symmetry index (BSI)
Prazo: Single point of assessment at inclusion
|
The amount of cortical lateralization during walking in stroke survivors compared to healthy controls. The score ranges from -1 to +1 with BSI = 0 reprenting perfect symmetry. Positive values represent higher power in the right hemishere compared to the left hemisphere, vice versa for negative values. For left side lesions, BSI was multiplied by -1. |
Single point of assessment at inclusion
|
|
Brain symmetry index (BSI)
Prazo: Single point of assessment 3 months after inclusion (only for stroke survivors)
|
The amount of cortical lateralization during walking in stroke survivors after a follow-up period of three months. The score ranges from -1 to +1 with BSI = 0 reprenting perfect symmetry. Positive values represent higher power in the right hemishere compared to the left hemisphere, vice versa for negative values. For left side lesions, BSI was multiplied by -1. |
Single point of assessment 3 months after inclusion (only for stroke survivors)
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Upper limb kinematics
Prazo: Single point of assessment at inclusion
|
Movements of the upper limb during walking measured by 3D kinematics and expressed as angles (°) |
Single point of assessment at inclusion
|
|
Upper limb kinematics
Prazo: Single point of assessment 3 months after inclusion (only for stroke survivors)
|
Movements of the upper limb during walking measured by 3D kinematics and expressed as angles (°) |
Single point of assessment 3 months after inclusion (only for stroke survivors)
|
|
Cortico-synergy coherence
Prazo: Single point of assessment at inclusion
|
The amount of coherence (i.e. phase locking) between the muscle synergies and cortical activity during walking in stroke survivors compared to healthy controls. Higher values (0-1) indicate a better linear association. |
Single point of assessment at inclusion
|
|
Cortico-synergy coherence
Prazo: Single point of assessment 3 months after inclusion (only for stroke survivors)
|
The amount of coherence (i.e phase locking) between the muscle synergies and cortical activity during walking in stroke survivors after a follow-up period of three months. Higher values (0-1) indicate a better linear association. |
Single point of assessment 3 months after inclusion (only for stroke survivors)
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
National Institutes of Health Stroke Scale (NIHSS)
Prazo: Single point of assessment at inclusion (only for stroke survivors)
|
Quantifies the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The highest score is 42. |
Single point of assessment at inclusion (only for stroke survivors)
|
|
National Institutes of Health Stroke Scale (NIHSS)
Prazo: Single point of assessment 3 months after inclusion (only for stroke survivors)
|
Quantifies the general impairment caused by a stroke after a follow-up period of three months. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The highest score is 42. |
Single point of assessment 3 months after inclusion (only for stroke survivors)
|
|
Fugl-Meyer assesment - Upper limbs
Prazo: Single point of assessment at inclusion (only for stroke survivors)
|
Assesses specifc motor impairments of the upper limbs of stroke survivors. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively. |
Single point of assessment at inclusion (only for stroke survivors)
|
|
Fugl-Meyer assesment - Upper limbs
Prazo: Single point of assessment 3 months after inclusion (only for stroke survivors)
|
Assesses specifc motor impairments of the upper limbs of stroke survivors after a follow-up period of three months. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively. |
Single point of assessment 3 months after inclusion (only for stroke survivors)
|
|
Tardieu scale
Prazo: Single point of assessment at inclusion (only for stroke survivors)
|
Quantifies spasticity by assessing the muscle's response (0-5) to different stretch velocities (V1, V2 or V3) and by determining the spasticity angle (R1 or R2). |
Single point of assessment at inclusion (only for stroke survivors)
|
|
Tardieu scale
Prazo: Single point of assessment 3 months after inclusion (only for stroke survivors)
|
Quantifies spasticity by assessing the muscle's response (0-5) to different stretch velocities (V1, V2 or V3) and by determining the spasticity angle (R1 or R2). |
Single point of assessment 3 months after inclusion (only for stroke survivors)
|
|
10 Meter Walking Test
Prazo: Single point of assessment at inclusion (only for stroke survivors)
|
Examins the walking capacity of a stroke survivor by measuring how long it takes to walk a distance of 10 meters (in seconds). |
Single point of assessment at inclusion (only for stroke survivors)
|
|
10 Meter Walking Test
Prazo: Single point of assessment 3 months after inclusion (only for stroke survivors)
|
Examins the walking capacity of a stroke survivor by measuring how long it takes to walk a distance of 10 meters (in seconds). |
Single point of assessment 3 months after inclusion (only for stroke survivors)
|
|
Fugl-Meyer assesment - Lower limbs
Prazo: Single point of assessment at inclusion (only for stroke survivors)
|
Assesses specifc motor impairments of the lower limbs of stroke survivors. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively. |
Single point of assessment at inclusion (only for stroke survivors)
|
|
Fugl-Meyer assesment - Lower limbs
Prazo: Single point of assessment 3 months after inclusion (only for stroke survivors)
|
Assesses specifc motor impairments of the lower limbs of stroke survivors after a follow-up period of three months. The Fugl-Meyer Assessment scale is an ordinal scale that has 3 points for each item. A zero score is given for the item if the subject cannot do the task. A score of 1 is given when the task is performed partially and a score of 2 is given when the task is performed fully. However, reflex activity is measured using 2 points only, with a score of 0 or 2 for absence and presence of reflex respectively. |
Single point of assessment 3 months after inclusion (only for stroke survivors)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Anke Van Bladel, PhD, Ghent University and Ghent University Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- ONZ-2024-0089
- 11PEU24N (Número de outro subsídio/financiamento: FWO)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .